Vascular disrupting agents

Antiangiogenic Cancer Therapy

Volumn , Issue , 2007, Pages 329-364

  Chaplin, David J ^a   Dougherty, Graeme J ^b   Siemann, Dietmar W ^c  

^a OXiGENE Inc   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84981260953     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420004298     Document Type: Chapter

References (212)

1. Folkman, J. Tumor angiogenesis: therapeutic implications. N Engl J Med, 285, 1182, 1971.
2. Folkman, J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg, 175, 409, 1972.
3. Folkman, J. Tumor angiogenesis: role in regulation of tumor growth. Symp Soc Dev Biol, 30, 43, 1974.
4. Folkman, J. Tumor angiogenesis: a possible control point in tumor growth. Ann Intern Med, 82, 96, 1975.
5. Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 350, 2335, 2004.
6. Denekamp, J. Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer, 45, 136, 1982.
7. Denekamp, J. Vascular endothelium as the vulnerable element in tumours. Acta Radiologica Oncol, 23, 217, 1984.
8. Denekamp, J. Endothelial cell attack as a novel approach to cancer therapy. Cancer Topics, 6, 6, 1986.
9. Denekamp, J., Hill, S.A., and Hobson, B. Vascular occlusion and tumour cell death. Eur J Cancer Clin Oncol, 19, 271, 1983.
10. Chaplin, D.J. and Horsman, M.R. The influence of tumour temperature on ischemia-induced cell death: potential implications for the evaluation of vascular mediated therapies. Radiother Oncol, 30, 59, 1994.
11. Parkins, C.S. et al. Ischaemia induced cell death in tumors: importance of temperature and pH. Int J Radiat Oncol Biol Phys, 29, 499, 1994.
12. Boyland, E. and Boyland, M.E. Studies in tissue metabolism. IX. The action of colchicine and B. typhosus extract. Biochem J, 31, 454, 1937.
13. Ludford, R.J. Colchicine in the experimental chemotherapy of cancer. J Natl Cancer Inst, 6, 89, 1945.
14. Ludford, R.J. Factors determining the action of colchicine on tumour growth. Br J Cancer, 2, 75, 1948.
15. Seed, L., Slaughter, D.P., and Limarzi, L.R. Effect of colchicine on human carcinoma. Surgery, 7, 696, 1940.
16. Leiter, J. et al. Damage induced in sarcoma 37 with podophyllin, podophyllotoxin alpha-peltatin, beta-peltatin, and quercetin. J Natl Cancer Inst, 10, 1273, 1950.
17. Andervont, H.B. Effect of colchicine and bacterial products on transplantable and spontaneous tumors in mice. J Natl Cancer Inst, 1, 361, 1940.
18. Mottram, J.C. Observations on the combined action of colloidal lead and radiation on tumours. Brit Med J, 1, 928, 1928.
19. Leiter, J. et al. Damage induced in sarcoma 37 with chemical agents. II. Trivalent and pentavalent arsenicals. J Natl Cancer Inst, 13, 365, 1952.
20. Hill, S.A. et al. Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer, 9, 1320, 1993.
21. Hill, S.A. et al. The effect of vinca alkaloids on tumour blood flow. Adv Exp Med Biol, 345, 417, 1994.
22. Chaplin, D.J. et al. Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br J Cancer, 27 (Suppl), S86, 1996.
23. Pettit, G.R., Cragg, G.M., and Singh, S.B. Antineoplastic agents, 122. Constituents of Combretum caffrum. J Nat Prod, 50, 386, 1987.
24. Aleksandrzak, K., McGown, A.T., and Hadfield, J.A. Antimitotic activity of diaryl compounds with structural features resembling combretastatin A-4. Anticancer Drugs, 9, 545, 1998.
25. Hatanaka, T. et al. Novel B-ring modified combretastatin analogues: syntheses and antineoplastic activity. Bioorg Med Chem Lett, 8, 3371, 1998.
26. Ohsumi, K. et al. Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships. J Med Chem, 41, 3022, 1998.
27. Pettit, G.R. et al. Antineoplastic agents. 379. Synthesis of phenstatin phosphate. J Med Chem, 41, 1688, 1998.
28. Lawrence, N.J. et al. Antimitotic and cell growth inhibitory properties of combretastatin A-4-like ethers. Bioorg Med Chem Lett, 11, 51, 2001.
29. Hadimani, M.B. et al. Synthesis, in vitro, and in vivo evaluation of phosphate ester derivatives of combretastatin A-4. Bioorg Med Chem Lett, 13, 1505, 2003.
30. Liou, J.P. et al. Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents. J Med Chem, 47, 4247, 2004.
31. Perez-Melero, C. et al. A new family of quinoline and quinoxaline analogues of combretastatins. Bioorg Med Chem Lett, 14, 3771, 2004.
32. Sun, L. et al. Examination of the 1,4-disubstituted azetidinone ring system as a template for combretastatin A-4 conformationally restricted analogue design. Bioorg Med Chem Lett, 14, 2041, 2004.
33. Prinz, H. Recent advances in the field of tubulin polymerization inhibitors. Expert Rev Anticancer Ther, 2, 695, 2002.
34. Dark, G.G. et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res, 57, 1829, 1997.
35. Tozer, G.M. et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res, 59, 1626, 1999.
36. Murata, R., Overgaard, J., and Horsman, M.R. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Int J Radiat Biol, 77, 195, 2001.
37. Watts, M.E. et al. Effects of novel and conventional anti-cancer agents on human endothelial permeability: influence of tumour secreted factors. Anticancer Res, 17, 71, 1997.
38. Galbraith, S.M. et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res, 21, 93, 2001.
39. Chaplin, D.J. and Dougherty, G.J. Tumour vasculature as a target for cancer therapy. Br J Cancer, 80 (Suppl 1), 57, 1999.
40. Kanthou, C. and Tozer, G.M. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood, 99, 2060, 2002.
41. Tozer, G.M. et al. The biology of the combretastatins as vascular targeting agents. Int J Exp Pathol, 83, 21, 2002.
42. Brooks, A.C. et al. The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro. Anticancer Res, 23, 3199, 2003.
43. Parkins, C.S. et al. Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide. Br J Cancer, 83, 811, 2000.
44. Hori, K. et al. Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. Jap J Cancer Res, 90, 1026, 1999.
45. Hori, K., Saito, S., and Kubota, K. A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. Br J Cancer, 86, 1604, 2002.
46. Hori, K. and Saito, S. Induction of tumour blood flow stasis and necrosis: a new function for epinephrine similar to that of combretastatin A-4 derivative AVE8062 (AC7700). Br J Cancer, 90, 549, 2004.
47. Platts, S.H. et al. Alteration of microtubule polymerization modulates arteriolar vasomotor tone. Am J Physiol, 277, H100, 1999.
48. Honess, D.J., Hylands, F., Chaplin, D.J., and Tozer, G.M. Comparison of strategies to overcome the hypertensive effect of combretastatin-A-4-phosphate in a rat model. Br J Cancer, 86, S118, 2002.
49. Pettit, G.R. and Lippert, J.W. Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs. Anti-Cancer Drug Des, 15, 203, 2000.
50. Hill, S.A. et al. Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models. Int J Cancer, 102, 70, 2002.
51. Holwell, S.E. et al. Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate. Anticancer Res, 22, 3933, 2002.
52. Hua, J. et al. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate. Anticancer Res, 23, 1433, 2003.
53. Kirwan, I.G. et al. Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate. Clin Cancer Res, 10, 1446, 2004.
54. Blakey, D.C. et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res, 8, 1974, 2002.
55. Robinson, S.P. et al. Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer, 88, 1592, 2003.
56. McIntyre, D.J. et al. Single dose of the antivascular agent, ZD6126 (N-acetylcolchinol-Ophosphate), reduces perfusion for at least 96 h in the GH3 prolactinoma rat tumor model. Neoplasia, 6, 150, 2004.
57. Dowlati, A. et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res, 62, 3408, 2002.
58. Stevenson, J.P. et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncology, 21, 4428, 2003.
59. Rustin, G.J. et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol, 21, 2815, 2003.
60. Galbraith, S.M. et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol, 21, 2831, 2003.
61. Anderson, H.L. et al. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol, 21, 2823, 2003.
62. Young, S.L. and Chaplin, D.J. Combretastatin A4 phosphate: background and current clinical status. Expert Opin Investig Drugs, 13, 1171, 2004.
63. West, C.M. and Price, P. Combretastatin A4 phosphate. Anticancer Drugs, 15, 179, 2004.
64. Gadgeel, S.M. et al. A dose-escalation study of the novel vascular-targeting agent ZD6126, in patients with solid tumors. Abstract 438. Am Soc Clin Oncol Annu Meet, 2002.
65. Tolcher, A.W. et al. Phase I, pharmacokinetic, and DCE-MRI correlative study of AVE8062A, an antivascular combretastatin analogue, administered weekly for 3 weeks every 28-days. Abstract 834. Am Soc Clin Oncol Annu Meet, 2003.
66. Evelhoch, J.L. et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res, 10, 3650, 2004.
67. Sessa, C. et al. A pharmacokinetic and DCE-MRI-dynamic phase I study of the antivascular combretastatin analogue AVE8062A administered every 3 weeks. Abstract 5827. 96th Annual Meeting of the American Association for Cancer Research. Anaheim, CA, 2005.
68. Rustin, G.J. et al. A Phase Ib trial of combretastatin A-4 phosphate (CA4P) in combination with carboplatin or paclitaxel chemotherapy in patients with advanced cancer. Abstract 3013. Am Soc Clin Oncol Annu Meet, 2005.
69. Corbett, T.H. et al. Activity of flavone acetic acid (NSC-347512) against solid tumors of mice. Invest New Drugs, 4, 207, 1986.
70. Smith, G.P. et al. Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours. Eur J Cancer Clin Oncol, 23, 1209, 1987.
71. Bibby, M.C. et al. Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy. J Natl Cancer Inst, 81, 216, 1989.
72. Hill, S.A., Williams, K.B., and Denekamp, J. A comparison of vascular-mediated tumor cell death by the necrotizing agents GR63178 and flavone acetic acid. Int J Radiat Oncol Biol Phys, 22, 437, 1992.
73. Evelhoch, J.L. et al. Flavone acetic acid (NSC 347512)-induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopy. Cancer Res, 48, 4749, 1988.
74. Hill, S.A., Williams, K.B., and Denekamp, J. Vascular collapse after flavone acetic acid: a possible mechanism of it’s anti-tumour action. Eur J Cancer Clin Oncol, 25, 1419, 1989.
75. Mahadevan, V. et al. Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown. Cancer Res, 50, 5537, 1990.
76. Kerr, D.J. et al. Phase I and pharmacokinetic study of flavone acetic acid. Cancer Res, 47, 6776, 1987.
77. Weiss, R.B. et al. Phase I and clinical pharmacology study of intravenous flavone acetic acid (NSC 347512). Cancer Res, 48, 5878, 1988.
78. Kerr, D.J. et al. Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma. Br J Cancer, 60, 104, 1989.
79. O’Reilly, S.M. et al. Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma: I. Clinical and vascular studies. Br J Cancer, 67, 1342, 1993.
80. Rewcastle, G.W. et al. Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem, 34, 217, 1991.
81. Ching, L.M. et al. Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Cancer Res, 54, 870, 1994.
82. Ching, L.M. et al. Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer, 86, 1937, 2002.
83. Baguley, B.C., Zhuang, L., and Kestell, P. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine and colchicine: relation to vascular effects. Oncol Res, 9, 55, 1997.
84. Baguley, B.C. Antivascular therapy of cancer: DMXAA. Lancet Oncol, 4, 141, 2003.
85. Tozer, G.M., Kanthou, C., and Baguley, B.C. Disrupting tumour blood vessels. Nat Rev Cancer, 5, 423, 2005.
86. Zhao, L. et al. Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling. Clin Cancer Res, 9, 6545, 2003.
87. Siemann, D., Chaplin, D., and Horsman, M. Vascular-targeting therapies for treatment of malignant disease. Cancer, 100, 2491, 2004.
88. Rustin, G.J. et al. 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent:phase I clinical and pharmacokinetic study. Br J Cancer, 88, 1160, 2003.
89. Jameson, M.B. et al. Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer, 88, 1844, 2003.
90. Galbraith, S.M. et al. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol, 20, 3826, 2002.
91. Blaschuk, O.W. and Rowlands, T.M. Cadherins as modulators of angiogenesis and the structural integrity of blood vessels. Cancer Metast Rev, 19, 1, 2000.
92. Lepekhin, E. et al. Early and long term effects of exherin on tumor vasculature. Abstract 883. Am Soc Clin Oncol Annu Meet, 2003.
93. Jonker, D.J. et al. A phase I study of the novel molecularly targeted vascular targeting agent exherinTM (ADH-1), shows activity in some patients with refractory solid tumors stratified according to N-cadherin expression. Abstract 3038. Am Soc Clin Oncol Annu Meet, 2005.
94. Burrows, F.J. and Thorpe, P.E. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci USA, 90, 8996, 1993.
95. Burrows, F. and Thorpe, P. Vascular targeting-a new approach to the therapy of solid tumors. Pharmacol Ther, 64, 155, 1994.
96. Denekamp, J. Vascular attack as a therapeutic strategy for cancer. Cancer Metast Rev, 9, 267, 1990.
97. Denekamp, J. Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol, 66, 181, 1993.
98. Zhang, H. et al. Transcriptional profiling of human microvascular endothelial cells in the proliferative and quiescent state using cDNA arrays. Angiogenesis, 3, 211, 1999.
99. Kozian, D. and Augustin, H. Rapid identification of differentially expressed endothelial cell genes by RNA display. Biochem Biophys Res Commun, 209, 1068, 1995.
100. Prols, F., Loser, B., and Marx, M. Differential expression of osteopontin, PC4, and CEC5, a novel mRNA species, during in vitro angiogenesis. Exp Cell Res, 239, 1, 1998.
101. Fabbri, M. et al. A functional monoclonal antibody recognizing the human alpha 1-integrin I-domain. Tissue Antigens, 48, 47, 1996.
102. Enenstein, J. and Kramer, R. Confocal microscopic analysis of integrin expression on the microvasculature and its sprouts in the neonatal foreskin. J Invest Dermatol, 103, 381, 1994.
103. Brooks, P. et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 79, 1157, 1994.
104. Brooks, P. et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest, 96, 1815, 1995.
105. Senger, D. et al. Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins. Proc Natl Acad Sci USA, 94, 13612, 1997.
106. Huminiecki, L. and Bicknell, R. In silico cloning of novel endothelial-specific genes. Genome Res, 10, 1796, 2000.
107. Ho, M. et al. Identification of endothelial cell genes by combined database mining and microarray analysis. Physiol Genomics, 13, 249, 2003.
108. Gerritsen, M. et al. In silico data filtering to identify new angiogenesis targets from a large in vitro gene profiling data set. Physiol Genomics, 10, 13, 2002.
109. Mailhos, C. et al. Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation, 69, 135, 2001.
110. Liu, Z. et al. Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol, 23, 14, 2003.
111. Oh, P. et al. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature, 429, 629, 2004.
112. Durr, E. et al. Direct proteomic mapping of the lung microvascular endothelial cell surface in vivo and in cell culture. Nat Biotechnol, 22, 985, 2004.
113. Matsubara, S. et al. Analysis of endoglin expression in normal brain tissue and in cerebral arteriovenous malformations. Stroke, 31, 2653, 2000.
114. Arap, W. et al. Steps toward mapping the human vasculature by phage display. Nat Med, 8, 121, 2002.
115. Kolonin, M., Pasqualini, R., and Arap, W. Molecular addresses in blood vessels as targets for therapy. Curr Opin Chem Biol, 5, 308, 2001.
116. Trepel, M., Arap, W., and Pasqualini, R. In vivo phage display and vascular heterogeneity:implications for targeted medicine. Curr Opin Chem Biol, 6, 399, 2002.
117. Christian, S. et al. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol, 163, 871, 2003.
118. Matsuno, F. et al. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res, 5, 371, 1999.
119. Tsunoda, S. et al. Specific binding of TES-23 antibody to tumour vascular endothelium in mice, rats and human cancer tissue: a novel drug carrier for cancer targeting therapy. Br J Cancer, 81, 1155, 1999.
120. Ran, S. et al. Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice. Clin Cancer Res, 11, 1551, 2005.
121. Huang, X., Bennett, M., and Thorpe, P. A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice. Cancer Res, 65, 4408, 2005.
122. Marty, C. et al. Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes. Br J Cancer, 87, 106, 2002.
123. Olson, T. et al. Targeting the tumor vasculature: inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate. Int J Cancer, 73, 865, 1997.
124. Wild, R. et al. VEGF-DT385 toxin conjugate inhibits mammary adenocarcinoma development in a transgenic mouse model of spontaneous tumorigenesis. Breast Cancer Res Treat, 85, 161, 2004.
125. Ran, S. et al. Infarction of solid Hodgkin’s tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res, 58, 4646, 1998.
126. Nilsson, F. et al. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res, 61, 711, 2001.
127. Liu, C. et al. Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. Cancer Res, 62, 5470, 2002.
128. Hu, P. et al. Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis. Cancer Res, 63, 5046, 2003.
129. Nabel, E., Plautz, G., and Nabel, G. Gene transfer into vascular cells. J Am College Cardiol, 17, 189B, 1991.
130. Richter, M. et al. Adeno-associated virus vector transduction of vascular smooth muscle cells in vivo. Physiol Genomics, 2, 117, 2000.
131. Nicklin, S. et al. Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol Ther, 4, 174, 2001.
132. Pajusola, K. et al. Cell-type-specific characteristics modulate the transduction efficiency of adenoassociated virus type 2 and restrain infection of endothelial cells. J Virol, 76, 11530, 2002.
133. Wickham, T. et al. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell, 73, 309, 1993.
134. Greber, U. et al. Stepwise dismantling of adenovirus 2 during entry into cells. Cell, 75, 477, 1993.
135. Wang, K. et al. Adenovirus internalization and infection require dynamin. J Virol, 72, 3455, 1998.
136. Bergelson, J. Receptors mediating adenovirus attachment and internalization. Biochem Pharmacol, 57, 975, 1999.
137. Gaggar, A., Shayakhmetov, D., and Lieber, A. CD46 is a cellular receptor for group B adenoviruses. Nat Med, 9, 1408, 2003.
138. Wickham, T. et al. Targeted adenovirus-mediated gene delivery to T cells via CD3. J Virol, 71, 7663, 1997.
139. Nicklin, S. et al. In vitro and in vivo characterisation of endothelial cell selective adenoviral vectors. J Gene Med, 6, 300, 2004.
140. Liu, L. et al. Incorporation of tumor vasculature targeting motifs into moloney murine leukemia virus env escort proteins enhances retrovirus binding and transduction of human endothelial cells. J Virol, 74, 5320, 2000.
141. Masood, R. et al. Retroviral vectors bearing IgG-binding motifs for antibody-mediated targeting of vascular endothelial growth factor receptors. Int J Mol Med, 8, 335, 2001.
142. Nicklin, S. and Baker, A. Tropism-modified adenoviral and adeno-associated viral vectors for gene therapy. Curr Gene Ther, 2, 273, 2002.
143. White, S. et al. Targeted gene delivery to vascular tissue in vivo by tropism-modified adenoassociated virus vectors. Circulation, 109, 513, 2004.
144. Muller, O. et al. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol, 21, 1040, 2003.
145. Graulich, W. et al. Cell type specificity of the human endoglin promoter. Gene, 227, 55, 1999.
146. Nicklin, S. et al. Analysis of cell-specific promoters for viral gene therapy targeted at the vascular endothelium. Hypertension, 38, 65, 2001.
147. Reynolds, P. et al. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotechnol, 19, 838, 2001.
148. Korhonen, J. et al. Endothelial-specific gene expression directed by the tie gene promoter in vivo. Blood, 86, 1828, 1995.
149. De Palma, M., Venneri, M., and Naldini, L. In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. Hum Gene Ther, 14, 1193, 2003.
150. Cowan, P. et al. Targeting gene expression to endothelial cells in transgenic mice using the human intercellular adhesion molecule 2 promoter. Transplantation, 62, 155, 1996.
151. Velasco, B. et al. Vascular gene transfer driven by endoglin and ICAM-2 endothelial-specific promoters. Gene Ther, 8, 897, 2001.
152. Richardson, T., Kaspers, J., and Porter, C. Retroviral hybrid LTR vector strategy: functional analysis of LTR elements and generation of endothelial cell specificity. Gene Ther, 11, 775, 2004.
153. Dancer, A. et al. Expression of thymidine kinase driven by an endothelial-specific promoter inhibits tumor growth of Lewis lung carcinoma cells in transgenic mice. Gene Ther, 10, 1170, 2003.
154. Jager, U., Zhao, Y., and Porter, C. Endothelial cell-specific transcriptional targeting from a hybrid long terminal repeat retrovirus vector containing human prepro-endothelin-1 promoter sequences. J Virol, 73, 9702, 1999.
155. Mavria, G., Jager, U., and Porter, C. Generation of a high titre retroviral vector for endothelial cell-specific gene expression in vivo. Gene Ther, 7, 368, 2000.
156. Varda-Bloom, N. et al. Tissue-specific gene therapy directed to tumor angiogenesis. Gene Ther, 8, 819, 2001.
157. Cho, J. et al. Development of an efficient endothelial cell specific vector using promoter and 50 untranslated sequences from the human preproendothelin-1 gene. Exp Mol Med, 35, 269, 2003.
158. Greenberger, S. et al. Transcription-controlled gene therapy against tumor angiogenesis. J Clin Invest, 113, 1017, 2004.
159. Dai, C., McAninch, R., and Sutton, R. Identification of synthetic endothelial cell-specific promoters by use of a high-throughput screen. J Virol, 78, 6209, 2004.
160. Li, X. et al. Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences. Nat Biotechnol, 17, 241, 1999.
161. Edelman, G. et al. Synthetic promoter elements obtained by nucleotide sequence variation and selection for activity. Proc Natl Acad Sci USA, 97, 3038, 2000.
162. Carpenito, C. et al. Exploiting the differential production of angiogenic factors within the tumor microenvironment in the design of a novel vascular-targeted gene therapy-based approach to the treatment of cancer. Int J Radiat Oncol Biol Phys, 54, 1473, 2002.
163. Cross, M. et al. VEGF-receptor signal transduction. Trends Biochem Sci, 28, 488, 2003.
164. Hayes, G. et al. Alternative splicing as a novel of means of regulating the expression of therapeutic genes. Cancer Gene Ther, 9, 133, 2002.
165. Hayes, G. et al. Molecular mechanisms regulating the tumor-targeting potential of splice-activated gene expression. Cancer Gene Ther, 11, 797, 2004.
166. Thorpe, P.E. Vascular targeting agents as cancer therapeutics. Clin Cancer Res, 10, 415, 2004.
167. Huang, X. et al. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science, 275, 547, 1997.
168. Siemann, D.W. Therapeutic strategies that selectively target and disrupt established tumor vasculature. Hematol Oncol Clin North Am, 18, 1023, 2004.
169. Landuyt, W. et al. In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int J Radiat Oncol Biol Phys, 49, 443, 2001.
170. Siemann, D.W. and Shi, W. Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy. Semin Radiat Oncol, 13, 53, 2003.
171. Siemann, D.W. and Rojiani, A.M. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large advanced tumors. Int J Radiat Oncol Biol Phys, in press, 62, 846, 2005.
172. Grosios, K. et al. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer, 81, 1318, 1999.
173. Davis, P.D. et al. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res, 62, 7247, 2002.
174. Chaplin, D.J., Pettit, G.R., and Hill, S.A. Anti-vascular approaches to solid tumour therapy:evaluation of combretastatin A4 phosphate. Anticancer Res, 19, 189, 1999.
175. Li, L., Rojiani, A.M., and Siemann, D.W. Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi’s sarcoma. Acta Oncol, 41, 91, 2002.
176. Siemann, D.W. and Shi, W. Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int J Radiat Oncol Biol Phys, 60, 1233, 2004.
177. Grosios, K. et al. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res, 20, 229, 2000.
178. Cliffe, S. et al. Combining bioreductive drugs (SR4233 or SN23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Int J Radiat Oncol Biol Phys, 29, 373, 1994.
179. Lash, C.J. et al. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer, 78, 439, 1998.
180. Pruijn, F.B. et al. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol, 39, 541, 1997.
181. Siim, B.G. et al. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol, 51, 43, 2003.
182. Nelkin, B.D. and Ball, D.W. Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma. Oncol Rep, 8, 157, 2001.
183. Siemann, D.W. et al. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer, 99, 1, 2002.
184. Konerding, M.A., Miodonski, A.J., and Lametschwandtner, A. Microvascular corrosion casting in the study of tumor vascularity: a review. Scanning Microsc, 9, 1233, 1995.
185. Vaupel, P. et al. Blood flow, oxygen consumption, and tissue oxygenation of human breast cancer xenografts in nude rats. Cancer Res, 47, 3496, 1987.
186. Vaupel, P., Kallinowski, F., and Okunieff, P. Blood flow, oxygen consumption and tissue oxygenation of human tumors. Adv Exp Med Biol, 277, 895, 1990.
187. Hockel, M. et al. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol, 26, 45, 1993.
188. Brizel, D.M. et al. Pretreatment oxygenation profiles of human soft tissue sarcomas. Int J Radiat Oncol Biol Phys, 30, 635, 1994.
189. Nordsmark, M., Overgaard, M., and Overgaard, J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol, 41, 31, 1996.
190. Knocke, T.H. et al. Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol, 53, 99, 1999.
191. Horsman, M.R. and Murata, R. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys, 57, 1047, 2003.
192. Siemann, D.W. and Horsman, M.R. Enhancement of radiation therapy by vascular targeting agents. Curr Opin Investig Drugs, 3, 1660, 2002.
193. Siemann, D.W. and Horsman, M.R. Targeting the tumor vasculature: a strategy to improve radiation therapy. Expert Rev Anticancer Ther, 4, 321, 2004.
194. Nishiguchi, I., Willingham, V., and Milas, L. Tumor necrosis factor as an adjunct to fractionated radiotherapy in the treatment of murine tumors. Int J Radiat Oncol Biol Phys, 18, 555, 1990.
195. Wilson, W.R. et al. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Int J Radiat Oncol Biol Phys, 42, 905, 1998.
196. Siemann, D.W. and Rojiani, A.M. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys, 53, 164, 2002.
197. Lew, Y.S. et al. Synergistic interaction with arsenic trioxide and fractionated radiation in locally advanced murine tumor. Cancer Res, 62, 4202, 2002.
198. Murata, R. et al. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiat Res, 156, 503, 2001.
199. Kimura, H. et al. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res, 56, 5522, 1996.
200. Horsman, M.R., Murata, R., and Overgaard, J. Combination studies with combretastatin and radiation: effects in early and late responding tissues. Radiother Oncol, 63 (Suppl 1), S50, 2002.
201. Murata, R. et al. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol, 60, 155, 2001.
202. Siemann, D.W. et al. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res, 11, 416, 2005.
203. O’Reilly, M.S. et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79, 315, 1994.
204. Yoon, S.S. et al. Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res, 59, 6251, 1999.
205. Liao, F. et al. Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis. Cancer Res, 60, 6805, 2000.
206. Ellis, L.M. et al. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist, 5 (Suppl 1), 11, 2000.
207. Fidler, I.J. and Ellis, L.M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell, 79, 185, 1994.
208. Wedge, S.R., Kendrew, J., Ogilvie, D.J., Hennequin, L.F., Brave, A.J., Ryan, A.J. et al. Combination of the VEGF receptor tyrosine kinase inhibitor ZD6474 and vascular-targeting agent ZD6126 produces an enhanced anti-tumor response. Proc Am Assoc Cancer Res, 43, 1081, 2002.
209. Siemann, D.W. and Shi, W. Dual Targeting of Tumor Vasculature: Combining Avastin with CA4P or OXi4503. Clin Cancer Res, 11, 8965, 2005.
210. Griggs, J. et al. Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4. Am J Pathol, 160, 1097, 2002.
211. Nambu, H. et al. Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization. Invest Ophthalmol Vis Sci, 44, 3650, 2003.
212. Siemann, D.W. Vascular Targeting Agents, in Horizons in Cancer Therapeutics: From Bench to Bedside, 3, 4, 2002.